openPR Logo
Press release

Liposarcoma Treatment Market Report 2016 - 2022: By Treatment type, End User, Regional Outlook and Key Player

12-03-2017 11:43 AM CET | Health & Medicine

Press release from: Persistence Market Research

Liposarcoma Treatment Market Report 2016 - 2022: By Treatment

Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs in the middle age or adults above the age of 40 and it can be well diagnosed with the help of excision biopsy. Liposarcoma can be of four types viz. well differentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma. The most common drugs used for the treatment of liposarcoma include ifosfamide and doxorubicin. Ifosfamide is often prescribed in combination with uromitexan in order to prevent bladder irritation and internal bleeding. Moreover, cisplatin, vincristine, etoposide, gemcitabine, docetaxel etc. can be used to prevent the recurrence of liposarcoma.

Report overview @ https://www.persistencemarketresearch.com/market-research/liposarcoma-treatment-market.asp

The market for liposarcoma is highly fragmented with large number of generic manufacturers. The global market for liposarcoma treatment is expected to grow moderately over the forecast period owing to low incidence rate of the disease. Some other factors which are anticipated to influence growth of global liposarcoma treatment market include lifestyle changes, incidence of genetic disorders, growing awareness through liposarcoma genome project etc. However, high cost of the treatment can be the major restraint for the growth of global liposarcoma treatment market.
Surgical therapy treatment segment is expected to account for major share in global liposarcoma treatment market as it is the choice of treatment recommended by majority of cancer specialists. Most of the physicians do not rely on chemotherapy for the liposarcoma treatment however, it can be used prior to the surgery to reduce the size of the tumor making it the second largest segment in terms of value in global liposarcoma treatment market. Radiation therapy treatment is used to avoid recurrence of the liposarcoma after surgery and contributes a minimal share in global liposarcoma treatment market.

Request to sample report @ https://www.persistencemarketresearch.com/samples/10109

Geographically, global liposarcoma treatment market is classified into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to lead the global liposarcoma treatment market due to relatively greater prevalence of the disease in the region. APAC and MEA regions are expected to witness steady market growth owing to lack of awareness about the disease.

Some of the key players in global liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc.,Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories and others. Recently FDA approved the new indication of Halaven (eribulin) to Esai Co. Ltd. and new drug application of Yondelis (Trabectedin) from Johnson & Johnson Private Limited for use in Europe, Russia and South Korea.

Buy now @ https://www.persistencemarketresearch.com/checkout/10109

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Liposarcoma Treatment Market Report 2016 - 2022: By Treatment type, End User, Regional Outlook and Key Player here

News-ID: 842285 • Views:

More Releases from Persistence Market Research

Anime Market Set to Grow Significantly, Reaching USD 54.1 Billion by 2031 Amid Rising Global Popularity
Anime Market Set to Grow Significantly, Reaching USD 54.1 Billion by 2031 Amid R …
The global anime market has evolved far beyond traditional television broadcasts to become a multifaceted entertainment ecosystem. Driven by digital transformation, streaming services, and cross-media collaborations, anime has expanded its footprint globally, appealing to diverse audiences across age groups. Anime now extends into gaming, merchandising, licensing, and international film distribution, creating multiple revenue streams beyond conventional formats. According to market projections, the anime market is expected to grow from US$31.9 billion
Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Reaching USD 82.4 Billion by 2031
Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Re …
The Artificial Intelligence as a Service (AIaaS) market has emerged as one of the most transformative segments in the global technology ecosystem. By providing AI capabilities on a subscription or pay-per-use model, AIaaS allows organizations to deploy advanced AI functionalities without the need for significant in-house infrastructure. This model has democratized access to AI, enabling small and medium-sized enterprises to leverage predictive analytics, natural language processing, and machine learning tools
Server Operating System Market Anticipated to Witness Robust Growth, Reaching USD 34.5 Billion by 2031
Server Operating System Market Anticipated to Witness Robust Growth, Reaching US …
The server operating system market is witnessing robust growth, driven by the rapid expansion of data centers and the surging adoption of cloud technologies across enterprises worldwide. Server operating systems form the backbone of modern IT infrastructure, enabling organizations to efficiently manage hardware resources, deploy applications, and maintain high levels of system reliability and security. As businesses increasingly migrate to cloud environments and data-intensive operations grow, demand for powerful, scalable,
Manufacturing Operations Management Software Industry Anticipated to Witness Rapid Growth, Reaching USD 69.8 Billion by 2032
Manufacturing Operations Management Software Industry Anticipated to Witness Rap …
The Manufacturing Operations Management (MOM) software market is rapidly emerging as a cornerstone of digital transformation in the manufacturing sector. As industries increasingly adopt Industry 4.0 practices, the need for advanced solutions that integrate production planning, real-time monitoring, quality control, and process optimization has surged. MOM software enables manufacturers to streamline operations, reduce production downtime, and improve overall efficiency, making it an indispensable tool across automotive, pharmaceutical, aerospace, and consumer

All 5 Releases


More Releases for Liposarcoma

Myxoid Round Cell Liposarcoma (MRCLS) Drug Market: An Overview
Myxoid Round Cell Liposarcoma (MRCLS) is a rare and aggressive form of cancer that arises from the fat cells of connective tissues. It primarily affects the soft tissues, including the limbs, trunk, and retroperitoneum, often leading to pain, swelling, and other debilitating symptoms. MRCLS is classified as a type of liposarcoma, a cancer that can appear in various forms, with the myxoid subtype being particularly distinct due to the presence
Liposarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Liposarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Liposarcoma, historical and forecasted epidemiology as well as the Liposarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Liposarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Liposarcoma market size from 2019 to 2032, segmented
Retroperitoneal Liposarcoma Treatment Market - Size, Outlook, and Opportunity An …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of
Liposarcoma Treatment Market to Register Steady Growth During 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs
Global Liposarcoma Treatment Market to Record Sturdy Growth by 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs
Future of Global Liposarcoma Treatment Market 2016 - 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs